GlycoSCORES technique accelerates protein therapy research
9 May 2018 | By European Pharmaceutical Review
Researchers have developed a new biotech technique that promises to accelerate research into protein therapies...
List view / Grid view
Proteomics
Machine learning may reveal cause-effect relationships in protein dynamics data
18 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A group of researchers is showing how artificial intelligence approaches can help identify cause-effect relationships within data...
Novel methodology increases resolution in oligodendrocyte proteomics
26 March 2018 | By European Pharmaceutical Review
Brazilian researchers combine mass spectrometry, 2-D liquid chromatography and ion mobility to identify over 10,000 proteins in brain cells possibly involved in schizophrenia.
The future of bioanalysis with microchip chromatography
4 January 2018 | By Johan Devenyns, Johan Devenyns - PharmaFluidics
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
Researchers discover new targets for approved cancer drug ceritinib
11 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
New study shows ALK inhibitor ceritinib may have the ability to be used for more than ALK-rearranged non-small cell lung cancer...
Computer model shows an optimal anti-amyloid treatment
2 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A group of scientists have created a computer model to analyse amyloid beta accumulation using published papers and clinical studies...
Your next clinical biomarker will be assayed by mass spectrometry….or not!
23 December 2014 | By Axel Ducret, Biochemist
This article will focus on some of the critical aspects of transition biomarkers discovered in classical (MS-based) proteomics workflows and on the challenges to be met before validated assays can become more routine in the clinical laboratory...
Engineering cells and proteins – creating pharmaceuticals
5 September 2014 | By Marco Casteleijn & Dominique Richardson, University of Helsinki
Pharmaceutical biotechnology is big business; it currently consists of 1/6 of the total volume of the pharmaceutical market and continues to grow steadily. Expression of therapeutic proteins is mainly done in living cells, although ‘cell free protein synthesis’ (CFPS) or ‘in-vitro transcription translation’ (IVTT) is beginning to emerge as an…
Issue #6 2013 – Digital edition
16 December 2013 | By European Pharmaceutical Review
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
Pharmaceutical proteomics: a journey from discovery and characterisation of targets to development of high-throughput assays
15 December 2013 | By Joerg Reinders, Institute of Functional Genomics, University of Regensburg
Proteomics has evolved during the last few years from a time-intensive, cost-intensive and hard-to-reproduce technique in basic research to a versatile and reliable tool in various areas of pharmaceutical research. The exploding progress in mass-spectrometry-compatible protein and peptide-separation methods led to the development of new approaches particularly suited for monitoring…
Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?
13 June 2013 | By Thierry Le Bihan, SynthSys and Institute of Structural and Molecular Biology, University of Edinburgh
In recent years, mass spectrometry (MS) based proteomics has moved from being a qualitative tool (used to mainly identify proteins) to a more reliable analysis tool, allowing relative quantitation as well as absolute quantitation of a large number of proteins. However, the developed quantitative methods are either specific for certain…
The role of proteomics in the development of personalised cancer medicine
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…
Follow: